Differentiated thyroid cancer and LENVIMA
A clinical study of LENVIMA showed:
59% (154 out of 261 people) of people taking LENVIMA did not have their cancer get worse compared to 14% (18 out of 131 people) on placebo at the time of follow-up
154 of 261 people
being treated with LENVIMA did not have their cancer get worse
18 of 131 people
being treated with a placebo did not have their cancer get worse
was the median* time people treated with LENVIMA did not have their cancer get worse compared to a median of 3.6 months for those taking placebo. That is approximately 5x longer with LENVIMA than with placebo
*Median: The middle number in a list of numbers arranged from lowest to highest.
65% (169 out of 261 people) treated with LENVIMA had their tumors either partially shrink (partial response) or become undetectable (complete response) compared to 2% (2 out of 131 people) of those treated with placebo
How does LENVIMA work?
Understanding what LENVIMA is and how it may work can help set expectations for your treatment journey.